Jaime Dodge, MD
Family Medicine · Vancouver, WANPI 1295753531
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,004 and has fallen 96.0% since, to $40 in 2025. Among family medicine clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$417
- Novo Nordisk$353
- AstraZeneca$309
- AbbVie$285
- Lilly USA, LLC$81
- GSK$70
- plus $387 from 15 others
What the payments were for
- Food & beverage$1,896100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 32 | $417 |
| Novo Nordisk | 26 | $353 |
| AstraZeneca | 16 | $309 |
| AbbVie(2 entities) | 17 | $285 |
| Lilly USA, LLC | 4 | $81 |
| GSK | 5 | $70 |
| Boehringer Ingelheim | 4 | $50 |
| Genentech USA, Inc. | 3 | $48 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Pfizer | 3 | $38 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Merck | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $22 |
| Upsher-smith Laboratories LLC | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Dermira, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$1,902 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Vancouver
- Rick JacksonVancouver$28K
- Bernard StupskiVancouver$17K
- Donald BenzVancouver$14K
- Noel GuzmanVancouver$9K
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.